LCN2 and central nervous system cancer: Although the precise role of MMP-9/NGAL activity in glioma patients remains unclear, the elevation of MMP-9/NGAL activity in glioma patients and subsequent loss and recovery of activity after surgery and regression suggest that MMP-9/NGAL can serve as useful biomarker to diagnose and predict prognosis of glioma patients.